Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optune + temozolomide with pembrolizumab versus placebo in newly diagnosed glioblastoma
2024-513550-30-00Phase 3Authorised
- Sponsor
- NovoCure
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in glioblastoma (GBM) comparing Optune + maintenance temozolomide + pembrolizumab with Optune + maintenance temozolomide + placebo (2 arms). Primary endpoint: Overall survival. Planned start Mar 2025; status: authorised.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-513550-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513550-30-00.